Period:
Draw Mode:
| Volume | 487,597 |
|
|||||
| News | (2) | ||||||
| Day High | 1.24 | Low High |
|||||
| Day Low | 1.14 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Invivyd Inc | IVVD | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.015 | 1.27% | 1.20 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.19 | 1.14 | 1.24 | 1.20 | 1.185 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,988 | 487,597 | $ 1.20 | $ 584,098 | - | 1.03 - 4.89 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:22:50 | 1 | $ 1.24 | USD |
Invivyd Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 131.03M | 109.19M | 17.74M | $ - | $ - | -2.23 | -21.50 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 3.13M | 1.90% |
Invivyd News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IVVD Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.38 | 1.48 | 1.03 | 1.32 | 216,532 | -0.18 | -13.04% |
| 1 Month | 1.77 | 1.945 | 1.03 | 1.54 | 218,959 | -0.57 | -32.2% |
| 3 Months | 1.57 | 2.68 | 1.03 | 1.85 | 228,222 | -0.37 | -23.57% |
| 6 Months | 3.00 | 4.09 | 1.03 | 2.30 | 265,530 | -1.80 | -60.0% |
| 1 Year | 4.70 | 4.89 | 1.03 | 2.53 | 287,414 | -3.50 | -74.47% |
| 3 Years | 4.70 | 4.89 | 1.03 | 2.53 | 287,414 | -3.50 | -74.47% |
| 5 Years | 4.70 | 4.89 | 1.03 | 2.53 | 287,414 | -3.50 | -74.47% |
Invivyd Description
| Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape. |